UDP-Xylose Inhibitor Development Service

UDP-Xylose Inhibitor Development Service

UDP-Xylose Inhibitor Development Service at CD BioGlyco

UDP-xylose is an important sugar nucleoside diphosphate that plays a key role in cells. The synthesis of UDP-xylose is usually accomplished through a multi-step biosynthetic pathway, which involves the catalytic reactions of multiple enzymes, including UDP-glucose dehydrogenase and xylosyltransferase. These enzymes start with the substrate glucose and a series of coenzymes such as NAD+, and ultimately generate UDP-xylose through a series of catalytic reactions. UDP-xylose serves as an important substrate involved in a variety of biological processes, such as glycosylation modification and cell wall synthesis. Therefore, inhibitors targeting UDP-xylose may become potential drug targets for the treatment of certain diseases. CD BioGlyco provides professional UDP-xylose inhibitor development services.

  • Compound screening service

CD BioGlyco uses a high-throughput screening approach to identify candidate compounds with potential UDP-xylose inhibitory activity from compound libraries, followed by structural optimization of the candidate compounds to improve their activity and selectivity.

  • Enzyme inhibitor design and optimization service

CD BioGlyco uses computer-aided drug design, molecular simulation, and other technologies to design and optimize UDP-xylose inhibitors for target enzymes.

  • Compound synthesis and analysis service

Based on the designed enzyme inhibitor scheme, CD BioGlyco synthesizes and optimizes candidate compounds to improve their drug properties, pharmacokinetic properties, and toxicological characteristics, and conducts isolation, purification, and structural identification of the synthesized compounds.

  • Bioactivity assessment

We evaluate the UDP-xylose inhibitory activity and cytotoxicity of candidate compounds in vitro cell experiments. By measuring the inhibitory constants and kinetic parameters of candidate compounds on the target enzyme, we further studied its interaction mechanism with UDP-xylose synthase.

UDP-Xylose inhibitor development service. Fig.1 UDP-Xylose inhibitor development service. (CD BioGlyco)


Technology: KM Plotter, Knockout of Ugdh

Journal: Cancer Letters

IF: 9.756

Published: 2020

Results: The authors investigated the importance of multiple UDP-glucose pathways (including UDP-xylose) in breast cancer metastasis. The authors knocked out Ugdh, a rate-limiting gene that mediates UDP-glucuronide production, in mouse breast cancer cells and found that Ugdh knockout impaired tumor growth and metastasis in vivo. Moreover, the authors used online tools to evaluate the relationship between high expression of genes in the UDP-glucose pathway and patient survival. Results indicated that Ugdh expression increases UDP-glucuronide production, whereas low UXS1 decreases UDP-glucuronide.

High Ugdh and low UXS1 expression versus patient survival.Fig.2 High Ugdh and low UXS1 expression versus patient survival. (Teoh, et al., 2020)


  • Immunomodulator research: UDP-xylose participates in some important glycoprotein modification processes in the immune system, such as glycosylation reactions related to complement activation. The development of inhibitors of UDP-xylose regulates the activity of the immune system and has potential application value in the research of immune-related diseases.
  • Anti-infective drug research: UDP-xylose is involved in the synthesis and modification of cell walls in some bacteria and fungi, and is an important glycosylation substrate. The development of inhibitors of UDP-xylose interferes with the synthesis process of bacterial and fungal cell walls and provides new anti-infective treatment strategies.
  • Bioengineering: UDP-xylose is a key substrate for the synthesis of complex sugar molecules and glycoproteins. The development of inhibitors of UDP-xylose regulates glycosylation reactions and is of great significance for the synthesis of complex sugar products in bioengineering.


  • CD BioGlyco has innovative research directions and methods in the field of UDP-xylose inhibitor development, which provides cutting-edge scientific insights and novel solutions.
  • CD BioGlyco has a multidisciplinary team composed of professionals with different disciplinary backgrounds, including experts in the fields of biochemistry, medicinal chemistry, computational chemistry, and bioengineering, who conduct research and development of UDP-xylose inhibitors from multiple perspectives.
  • CD BioGlyco has a complete quality research and development management system to ensure the reliability of UDP-xylose inhibitor development results and the accuracy of data.

CD BioGlyco has efficient project management capabilities and a one-stop Inhibitor Development Services, and we will provide clients with excellent UDP-xylose inhibitor development services. Please feel free to contact us if you would like to learn more about specific service details.


  1. Zimmer, B.M.; et al. Integration of sugar metabolism and proteoglycan synthesis by UDP-glucose dehydrogenase. Journal of Histochemistry & Cytochemistry. 2021, 69(1): 13-23.
  2. Teoh, S.T.; et al. UDP-glucose 6-dehydrogenase knockout impairs migration and decreases in vivo metastatic ability of breast cancer cells. Cancer Letters. 2020, 492: 21-30.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.